888-416-9305 info@abterrabio.com

Digital Proteomics is now Abterra Biosciences

Abterra Biosciences discovers fully human antibodies from patients

Truly human antibody therapeutics.

Humans mount lasting antibody responses to infectious diseases and cancer. Abterra Bio uses next-generation sequencing, mass spectrometry, and machine learning to comprehensively map the antibody response, and rapidly identify better therapeutic antibodies. We’ve built an interdisciplinary team of data scientists and biologists to re-imagine how antibody therapeutics are developed.

Abterra Bio technology is built on decades of experience in antibody sequencing and analysis. Click on the services below to see how we can help you!

Abterra Bio Reptor Hybridoma Sequencing

REPTOR™  

Next-Gen Sequencing Hybridoma

Abterra Bio Reptor Bulk B Cell Sequencing

REPTOR™  

Next-Gen Sequencing Bulk B Cells
Abterra Bio Reptor Hit Expansion

REPTOR™  

Next-Gen Sequencing Hit Expansion 
Abterra Bio Reptor Library Sequencing

REPTOR™  

Next-Gen Sequencing Display Library
Abterra Bio Alicanto Rabbit Antibody Discovery

ALICANTO®

Rabbit Monoclonal Antibody Discovery
Abterra Bio Alicanto Single Domain Antibody Discovery

ALICANTO®  

Single Domain (VHH) Antibody Discovery

Abterra Bio Alicanto Human Antibody Discovery

ALICANTO®

Human Antibody Discovery
Abterra Bio Valens Sequence Confirmation

VALENS™

Protein Sequence Confirmation
Abterra Bio Valens Antibody Protein Sequencing

VALENS™  

Antibody Protein Sequencing

Our partners’ success means everything to us

I have had great experiences using Abterra Bio’s Reptor platform. The data generated was highly valuable, and the team provided quick and open communication throughout the whole process.

Sandeep Kumar, PhD

Associate Director - Antibody Discovery & Engineering, Scholar Rock

Latest News

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Scientific Updates

Single-molecule Ig Repertoire Sequencing from Lama glama

In recent years, camelids have become more than hearty travel companions due to their unconventional adaptive immune systems. Conventional IgG antibodies are tetrameric molecules comprised of two heavy chains and two light chains with molecular weights of roughly ~150...

Constructing an Accurate Antibody Repertoire

What is an antibody repertoire?The immune repertoire is the collection of unique immunoglobulin and T-cell receptor sequences present in an individual at a particular time. At Digital Proteomics we focus primarily on the immunoglobulin, or B-cell receptor repertoires...

From RNA to Sequencing: QC Matters

Sequencing the immunoglobulin (Ig) repertoire provides us with important information on the adaptive immune response, and can help with the development of diagnostic and therapeutic applications. A single human can have an estimated 10¹¹ B cells with millions of...

De Novo Antibody Sequencing Process: An Overview

If you search the internet for ‘antibody sequencing’, you will be rewarded with a long list of resources and services. The terms used to describe antibody sequencing are overloaded and highly similar. We felt a single resource that explained the why and how of the de...

Social Media Posts

With the use of NGS, our Reptor software was able to analyze the clone diversity during the hybridoma generation process, clone overlap across 3 bulk samples, and relatives of screened hits that can be used for hit expansion. Read our new blog post below!

https://abterrabio.com/2021/11/16/ngs-during-the-hybridoma-generation-process/

Using our Valens de novo antibody sequencing technology, we were able to cover missing amino acids from a published anti-FLAG M2 antibody sequence. Click below to read more about our case study!

#antibody #sequencing #pharma #biotech
https://abterrabio.com/2021/10/05/de-novo-antibody-sequencing-case-study/

Load More...

Every day, we strive to help our partners and collaborators push the boundaries of their science.

Subscribe To Our Newsletter!

Don't miss out on the latest case studies, posters, and other news.

You have Successfully Subscribed!